Skip to main content
Premium Trial:

Request an Annual Quote

Horizon CombinatoRx Contracts with Otsuka for Screening of Drug Candidates

NEW YORK (GenomeWeb) – Horizon Discovery today announced that its CombinatoRx division has entered into a contract with Otsuka Pharmaceutical Development and Commercialization to perform in vitro cell line screening of certain OPDC candidates in development.

Horizon CombinatoRx will receive $835,000 for the work, which is to be substantially completed by the end of the year.

Horizon acquired CombinatoRx from Zalicus in June for about $8 million. CombinatoRx's Combination High-Throughput Screening platform and Chalice analytics software enables the screening and analysis of thousands of complementary drug combinations. Combined with Horizon's Genesis gene editing platform and X-MAN isogenic cell line technology, the company provides services that include new phenotypic cell-based screens with compound siRNA, shRNA, and sgRNA libraries.

"As combination therapies emerge as the standard of care in a range of indications, it is important that we identify effective multi-target mechanisms," Edwin Rock, senior director of global clinical development for OPDC, said in a statement. "Using the Horizon CombinatoRx platform to explore our clinical stage programs in the context of combinations may provide us with information to guide development."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.